Circulating miR-323-3p and miR-652: Candidate markers for the presence and progression of acute coronary syndromes

International Journal of Cardiology

Volumn 176, Issue 2, 2014, Pages 375-385

  Pilbrowa, Anna P ^a   Cordeddu, Lina ^b   Cameron, Vicky A ^a   Frampton, Chris M ^a   Troughton, Richard W ^a   Doughty, Robert N ^d   Whalley, Gillian A ^e   Ellis, Chris J ^d   Yandle, Timothy G ^a   Richards, A Mark ^a,c   Foo, Roger S Y ^b,c  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c National University Health Systems   (Singapore)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e Faculty of Science   (New Zealand)

Author keywords

Circulating microRNA; Myocardial infarction; Survival

Indexed keywords

ADRENOMEDULLIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMLODIPINE; ANTILIPEMIC AGENT; CLOPIDOGREL; ENDOTHELIN; MICRORNA; MICRORNA 103; MICRORNA 208A; MICRORNA 27B; MICRORNA 323 3P; MICRORNA 652; TROPONIN T; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MIRN323 MICRORNA, HUMAN; MIRN652 MICRORNA, HUMAN;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HOSPITAL READMISSION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; UNSTABLE ANGINA PECTORIS; VALIDATION STUDY; BLOOD; COHORT ANALYSIS; DISEASE COURSE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; VERY ELDERLY;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; RISK FACTORS;

EID: 84922397121     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.07.068     Document Type: Article

References (35)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet 2006; 367: 1747-57.
2. Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-5.
3. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids-The mix of hormones and biomarkers. Nat Rev Clin Oncol 2011; 8: 467-77.
4. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: Novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res 2012; 110: 483-95.
5. De Rosa S, Fichtlscherer S, Lehmann R, Assmus B, Dimmeler S, Zeiher AM. Transcoronary concentration gradients of circulating microRNAs. Circulation 2011; 124: 1936-44.
6. Adachi T, Nakanishi M, Otsuka Y, et al. PlasmamicroRNA 499 as a biomarker of acute myocardial infarction. Clin Chem 2010; 56: 1183-5.
7. Cheng Y, Tan N, Yang J, et al. A translational study of circulating cell-freemicroRNA-1 in acute myocardial infarction. Clin Sci 2010; 119: 87-95.
8. Corsten MF, Dennert R, Jochems S, et al. Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet 2010; 3: 499-506.
9. D'Alessandra Y, Devanna P, Limana F, et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J 2010; 31: 2765-73.
10. Kuwabara Y, Ono K, Horie T, et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ Cardiovasc Genet 2011; 4: 446-54.
11. Ai J, Zhang R, Li Y, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun 2010; 391: 73-7.
12. Zile MR, Mehurg SM, Arroyo JE, Stroud RE, DeSantis SM, Spinale FG. Relationship between the temporal profile of plasma microRNA and left ventricular remodeling in patients after myocardial infarction. Circ Cardiovasc Genet 2011; 4: 614-9.
13. Fichtlscherer S, De Rosa S, Fox H, et al. Circulating microRNAs in patients with coronary artery disease. Circ Res 2010; 107: 677-84.
14. de Boer HC, van Solingen C, Prins J, et al. Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease. Eur Heart J 2013; 34: 3451-7.
15. Widera C, Gupta SK, Lorenzen JM, et al. Diagnostic and prognostic impact of six circulatingmicroRNAs in acute coronary syndrome. J Mol Cell Cardiol 2011; 51: 872-85.
16. Zampetaki A, Willeit P, Tilling L, et al. Prospective study on circulating microRNAs and risk of myocardial infarction. J Am Coll Cardiol 2012; 60: 290-9.
17. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: 1014-21.
18. Brandt PW, Partridge JB, WattieWJ. Coronary arteriography; method of presentation of the arteriogram report and a scoring system. Clin Radiol 1977; 28: 361-5.
19. Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: Estimating the risk of 6-month postdischarge death in an international registry. J Am Med Assoc 2004; 291: 2727-33.
20. Yandle TG, Richards AM, Gilbert A, Fisher S, Holmes S, Espiner EA. Assay of brain natriuretic peptide (BNP) in human plasma: Evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab 1993; 76: 832-8.
21. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-proBNP): A new marker of cardiac impairment. Clin Endocrinol (Oxf) 1997; 47: 287-96.
22. Lewis LK, Smith MW, Yandle TG, Richards AM, Nicholls MG. Adrenomedullin(1-52) measured in human plasma by radioimmunoassay: Plasma concentration, adsorption, and storage. Clin Chem 1998; 44: 571-7.
23. Kitamura K, Tanaka T, Kato J, Eto T, Tanaka K. Regional distribution of immunoreactive endothelin in porcine tissue: Abundance in inner medulla of kidney. Biochem Biophys Res Commun 1989; 161: 348-52.
24. Blondal T, Jensby Nielsen S, Baker A, et al. Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods 2013; 59(1): S1-6.
25. Mestdagh P, Van Vlierberghe P, De Weer A, et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol 2009; 10: R64.
26. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002: 3[RESEARCH0034].
27. Wang GK, Zhu JQ, Zhang JT, et al. CirculatingmicroRNA: A novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 2010; 31: 659-66.
28. Allantaz F, Cheng DT, Bergauer T, et al. Expression profiling of human immune cell subsets identifies miRNA-mRNA regulatory relationships correlated with cell type specific expression. PLoS One 2012; 7: E29979.
29. Roderburg C,Mollnow T, Bongaerts B, et al. Micro-RNA profiling in human serum reveals compartment-specific roles of miR-571 and miR-652 in liver cirrhosis. PLoS One 2012; 7: E32999.
30. Nahrendorf M, Swirski FK, Aikawa E, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 2007; 204: 3037-47.
31. Lai CY, Yu SL, Hsieh MH, et al. MicroRNA expression aberration as potential peripheral blood biomarkers for schizophrenia. PLoS One 2011; 6: E21635.
32. Lulla RR, Costa FF, Bischof JM, et al. Identification of differentially expressed microRNAs in osteosarcoma. Sarcoma 2011; 2011: 732690.
33. Kehl DW, Iqbal N, Fard A, Kipper BA, De La Parra Landa A, Maisel AS. Biomarkers in acute myocardial injury. Transl Res 2012; 159: 252-64.
34. Miura K, Miura S, Yamasaki K, et al. Identification of pregnancy-associated microRNAs in maternal plasma. Clin Chem 2010; 56: 1767-71.
35. D'Alessandra Y, Carena MC, Spazzafumo L, et al. Diagnostic potential of plasmatic MicroRNA signatures in stable and unstable angina. PLoS One 2013; 8: E80345.